Sun Pharma Advanced Research Company is currently trading at Rs. 117.50, up by 4.20 points or 3.71% from its previous closing of Rs. 113.30 on the BSE.
The scrip opened at Rs. 113.20 and has touched a high and low of Rs. 119.05 and Rs. 107.00 respectively. So far 41964 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 413.40 on 31-Aug-2018 and a 52 week low of Rs. 107.00 on 09-Jul-2019.
Last one week high and low of the scrip stood at Rs. 120.00 and Rs. 107.00 respectively. The current market cap of the company is Rs. 3050.23 crore.
The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 5.75% and 25.79% respectively.
Sun Pharma Advanced Research Company (SPARC) has received Orphan Drug Designation from the US Food and Drug Administration (USFDA) for SCO-088 for the treatment of patients with Chronic Myeloid Leukemia (CML).
This is an important milestone in company’s journey to provide solution for patients who are not responding to the existing treatments available in the market. SCO-088 will fill the gap in the treatment of resistant CML.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
